What Is DSIP?

1. Where did the “sleep-inducing” name come from?

In Schoenenberger and Monnier’s 1977 experiment, researchers isolated a peptide from rabbits, synthesized it and compared it with related peptides. Across 58 rabbits, including controls, they recorded brain electrical activity after infusing the substances into the brain’s ventricular system. Synthetic DSIP increased delta and spindle activity on the electroencephalogram, or EEG.

Delta waves are slow brain waves associated with deep non-REM sleep. That animal result explains the name. It does not establish how a commercially supplied injection affects a human night of sleep.

Human biology also complicates the idea of DSIP as a simple sleep switch. Friedman and colleagues, 1994, sampled blood every 30 minutes for 24 hours in 12 healthy volunteers while recording sleep. DSIP-like immunoreactivity peaked around 3 p.m. and reached its minimum around 1 a.m. Levels were lower during REM sleep and somewhat lower during slow-wave sleep than during wakefulness.

“DSIP-like immunoreactivity” means material detected by an antibody assay. It does not prove that every signal came from intact, active DSIP. This observational study cannot predict the effects of an injection, but it challenges the assumption that higher circulating levels must mean deeper sleep.

2. Does DSIP work for sleep? The human trials

The clinical literature includes positive findings and unsuccessful attempts to reproduce a useful benefit. These trials measured sleep in a laboratory, often with polysomnography: recordings that combine brain waves with other physiological signals.

These summaries use the published abstracts. They do not supply missing effect sizes or assume that all studies used the same formulation, timing or eligibility criteria.

The positive 1987 study gives a reason to investigate DSIP further. The other blinded trials prevent treating that result as a dependable outcome. Differences in treatment duration and design could contribute to the disagreement, but the studies do not establish which explanation is correct.

Most participants here had chronic insomnia. Even a clear benefit in that population would need testing before applying it to a healthy person who already sleeps seven or eight hours and wants more recovery from training.

3. What does the “59% more sleep” result mean?

The number comes from Schneider-Helmert and colleagues’ 1981 healthy-volunteer experiment. Six people received morning intravenous DSIP or placebo in a double-blind crossover study. Researchers reported a 59% increase in median total sleep time during a 130-minute observation window after treatment.

That percentage describes total sleep during a short daytime window. It cannot tell you how many extra minutes of deep sleep to expect overnight. The same paper reported some favorable changes in the following night’s sleep, including shorter sleep onset, but the 59% figure belongs to the daytime observation.

Relative percentages also need a baseline to be useful. A large percentage change over a short observation can represent a very different practical benefit from an extra hour of nighttime sleep. The abstract does not provide the underlying medians needed to convert this result into an absolute difference in minutes.

4. Deep sleep, REM and recovery are different outcomes

Sleep efficiency is the proportion of time in bed spent asleep. Sleep latency is the time it takes to fall asleep. Slow-wave sleep describes a particular sleep stage. An improvement in one does not guarantee an improvement in the others.

In Monti’s 1987 trial, increased non-REM sleep reflected changes in stage 2. Slow-wave sleep and REM sleep did not change. This is a direct reason to question a blanket claim that DSIP reliably increases deep sleep.

Recovery adds another step. A sleep study would need to measure outcomes such as next-day performance, soreness or training capacity to support a recovery claim. The daytime performance findings in Schneider-Helmert’s trial are relevant to functioning, but they do not establish improved muscle repair or athletic adaptation.

What a wearable can tell you

Chinoy and colleagues, 2021, compared seven consumer sleep-tracking devices with polysomnography. Sleep-stage agreement varied, and devices tended to perform worse on disrupted nights. That study evaluated specific devices and algorithms; its results are not an accuracy score for every current watch or ring.

A higher “deep sleep” estimate after DSIP is an observation worth recording, but it cannot prove that DSIP increased EEG-defined slow-wave sleep. Device error, ordinary night-to-night variation and changes in sleep opportunity can all affect the comparison.

For a useful sleep record, include bedtime, wake time, remembered awakenings, perceived restfulness and next-day sleepiness alongside the wearable’s estimate. Also record changes in caffeine, alcohol, illness and training load. A personal log can reveal patterns to discuss with a clinician; it cannot establish efficacy from a few good nights.

5. Does DSIP lower cortisol or raise growth hormone?

Cortisol claims have been tested in humans. In Späth-Schwalbe and colleagues’ 1995 experiments, DSIP did not suppress ACTH or cortisol responses to corticotropin-releasing hormone. Those experiments included five men in each hormone-challenge condition. In another ten men, DSIP did not alter the midday ACTH and cortisol response to a meal.

ACTH is a pituitary hormone that helps stimulate cortisol release. The findings do not support a dependable cortisol-lowering effect in people. They also do not test every possible stress condition, so they cannot prove DSIP never affects this system.

The growth-hormone argument draws partly on Iyer and colleagues’ 1988 rat experiments. After sleep deprivation, blocking DSIP-related activity with an antibody injected into a brain ventricle prevented increases in slow-wave sleep and growth hormone seen in control animals.

That experiment investigated a possible physiological role in rats. It did not test whether injecting DSIP under human skin increases growth hormone, builds muscle or improves recovery. The brain-directed intervention and the species both limit the comparison.

6. What does newer DSIP research add?

DSIP research did not end with the older insomnia trials. Mu and colleagues’ 2024 study investigated DSIP joined to peptides intended to help it cross the blood-brain barrier. Researchers tested this fusion preparation in mice with chemically induced insomnia and measured sleep-related behavior and neurotransmitters.

The modified preparation produced more favorable neurotransmitter findings than DSIP alone in that model. It remains an animal experiment involving a different construct. A paper about a DSIP fusion peptide cannot validate the effectiveness of an ordinary DSIP vial, capsule or spray.

For readers following peptide research, check the full molecule named in the methods. Sharing “DSIP” in the title does not make two products interchangeable.

7. DSIP dosage, injections and half-life

The 1992 trial used 25 nmol/kg intravenously before three study nights. This is a description of an experimental regimen. It does not establish a self-treatment dose or a conversion to subcutaneous administration.

Intravenous infusion delivers material directly into the circulation. A subcutaneous injection must first be absorbed from tissue. Nasal and oral preparations introduce other absorption questions. Bioavailability depends on the preparation and route, so equal amounts on a label do not guarantee equal exposure.

The FDA’s 2026 review cites an eight-minute plasma half-life but found no pharmacokinetic information for the proposed subcutaneous route. A short clearance time does not determine how long a sleep effect lasts.

The six-person 1981 insomnia report described slight arousal during the first hour and sleep-promoting effects beginning in the second. That delayed response cannot supply a universal bedtime interval. It also does not justify increasing or repeating a dose when sleep fails to arrive quickly.

A half-life curve generated from an assumed value models that assumption. It cannot measure DSIP in your bloodstream or identify an effective nightly schedule. The studies above leave repeated cycles and long-term sleep enhancement unresolved.

8. DSIP side effects and nightly-use safety

The 2026 FDA briefing describes headache, nausea, vertigo and low blood pressure in intravenous withdrawal studies. Withdrawal symptoms complicate attribution. The review found no safety data for the proposed subcutaneous route.

Separately, FDA’s compounding safety page flags potential immune reactions and difficulties characterizing peptide impurities in emideltide products. A purity percentage does not establish sterility or clinical safety.

The absence of reported side effects in a six-person sleep experiment cannot establish that nightly use is safe. Uncommon reactions require much larger samples, and dependence or tolerance requires appropriate follow-up. Claims of “no hangover,” “no tolerance” or “zero withdrawal” need direct evidence for the formulation and duration being discussed.

DSIP has no FDA-approved use. The 2026 briefing concerns compounding-list evaluation, which does not approve a finished medicine.

9. DSIP vs Selank and sleep stacks

DSIP’s clinical papers mainly address sleep. Selank has a separate research history focused on anxiety. Reduced anxiety could make sleep easier for some people, but that possibility does not establish that Selank treats insomnia or that adding DSIP improves the result.

The studies reviewed here provide no controlled human comparison validating DSIP plus Selank, melatonin or other sleep aids. They also cannot establish interaction safety with prescription sedatives or alcohol. A plausible reason for combining substances supplies a research question, not a measured benefit.

For a biohacker already logging sleep, adding several compounds at once creates an attribution problem. If sleep improves while caffeine intake, training and three supplements change, the record cannot isolate DSIP’s contribution. If morning dizziness appears, the same uncertainty makes it harder to identify the cause.

Before interpreting a DSIP success story, look for the route, duration, baseline sleep pattern and actual outcome measured. Extra time asleep, a higher wearable score and better next-day functioning should each be reported separately.

10. DSIP FAQ

• What is DSIP used for?

  DSIP means delta sleep-inducing peptide, also called emideltide. Researchers have investigated it for sleep disorders, and biohackers discuss it for deeper sleep and recovery. Small human trials give conflicting results.

• Does DSIP increase deep sleep?

  A dependable increase has not been established in humans. In Monti and colleagues' 1987 blinded trial, slow-wave sleep did not change. Sleeping longer or falling asleep sooner also does not necessarily mean spending more time in deep sleep.

• Did DSIP increase sleep by 59% in a study?

  Yes, but the result measured median total sleep time in six healthy volunteers over 130 minutes after a morning intravenous infusion. It was not a 59% increase in overnight sleep or deep sleep.

• What is the recommended DSIP dosage?

  There is no established DSIP regimen for self-directed sleep enhancement. Doses studied through intravenous infusion cannot validate a subcutaneous injection, nasal spray, bedtime schedule or repeated cycle.

• What is DSIP's half-life?

  FDA's 2026 review cites an eight-minute plasma half-life but found no pharmacokinetic information for the proposed subcutaneous route. That figure cannot establish how long an injected product improves sleep or when to repeat it.

• Does DSIP lower cortisol?

  A 1995 human study found no suppression of ACTH or cortisol responses to a hormone challenge or a meal. That does not support using DSIP as a dependable cortisol-lowering treatment.

• Can DSIP make you feel more awake?

  A six-person insomnia study described slight arousal during the first hour, with sleep-promoting effects appearing in the second. That small observation cannot predict an individual's response or establish how often DSIP worsens sleep.

• Is DSIP safe for nightly use?

  Long-term nightly safety, tolerance and dependence risk have not been adequately established. Brief studies in small groups cannot determine uncommon adverse effects or the consequences of months of use.

• Can you stack DSIP with Selank or other sleep aids?

  The studies reviewed here do not establish the safety or added sleep benefit of DSIP with Selank, melatonin, sedatives or other peptides. Changing several substances together also makes benefits and side effects harder to attribute.

• Is DSIP FDA-approved?

  No. DSIP has no FDA-approved medical use as of September 20, 2026. Review for a compounding list does not constitute drug approval.

11. Sources